Laxmi Devisetty, MD, and Eva Kim, MD, look ahead at upcoming sessions focusing on geographic atrophy and refractive and ...

The funding is allocated to support the clinical development of the company's non-incisional refractive correction procedure ...

Ophthalmology Times - ophthalmology news, articles, and events in a timely and accurate manner for members of the ophthalmic ...

A recent study of AEYE-DS AI technology used in conjunction with the Topcon NW500 resulted in exceptional clinical diagnostic ...

QLS‑111 is a novel topical formulation using Qlaris Bio’s ATP-sensitive potassium channel modulator platform. QLS-111 lowers ...

The rationale for the study was anecdotal reports of the effects of breast milk used by mothers to treat blocked tear ducts, ...

The 36-week trial was a randomized, double-masked, parallel-group, active-controlled, multicenter evaluating CLS-AX (axitinib ...

According to the company, the suffix “-mod” in urcosimod denotes its classification as a modulator of key inflammatory and ...

PRISM evaluates 4D-150, a potential backbone therapy designed to provide multi-year sustained delivery of anti-VEGF ...

Martin Friedlander, MD, PhD, discusses phase 3 macular telangiectasia findings, highlighting the potential for a decade-long ...

M. Roy Wilson, presented the Shaffer-Hetherington-Hoskins Lecture at the Glaucoma 360 meeting held in San Francisco, ...

Shan Lin, MD, speaks to the new MIGS entering the glaucoma space and providing additional options for patients and providers ...